Merrimack Pharmaceuticals (MACK) announced Monday morning that its Phase 2 trial of MM-141 in addition to standard-of-care treatment in failed to meet its primary or secondary efficacy endpoints.
from RTT - Before the Bell https://ift.tt/2tF24CB
via IFTTT
No comments:
Post a Comment